Biomedical Engineering Reference
In-Depth Information
Reiffen D, Ward MR (2007) Branded generics as a strategy to limit cannibalization of
pharmaceutical markets. Manag Decis Econ 28(4-5):251-265
Rizzo JA (1999) Advertising and competition in the ethical pharmaceutical industry: the case of
antihypertensive drugs. J Law Econ 42(1):89-116
Saha A, Grabowski H, Birnbaum H, Greenberg P, Bizan O (2006) Generic competition in the US
pharmaceutical industry. Int J Econ Bus 13(1):15-38
Sandner P, Ziegelbauer K (2008) Product-related research: how research can contribute to success-
ful life-cycle management. Drug Discov Today 13(9/10):457-463
Scott Morton FM (2000) Barriers to entry, brand advertising, and generic entry in the US pharma-
ceutical industry. Int J Ind Organ 18(7):1085-1104
Shrank WH, Choudhry NK, Agnew-Blais J, Federman AD, Liberman JN, Liu J, Kesselheim AS,
Brookhart A, Fischer MF (2010) State generic substitution laws can lower drug outlays under
Medicaid. Health Aff 29(7):1383-1390
Shuchman M (2006) Delaying generic competition: corporate payoffs and the future of Plavix.
N Engl J Med 355(13):1297-1300
Statman M, Tyebjee TT (1981) Trademarks, patents, and innovation in the ethical drug industry.
J Market 45(3):71-81
Stremersch S, Tellis GJ (2002) Strategic bundling of products and prices: a new synthesis for mar-
keting. J Market 66(1):55-72
Teece DJ, Pisano G, Shuen A (1997) Dynamic capabilities and strategic management. Strat Manag
J 18(7):509-533
Vivian JC (2008) Generic-Substitution Laws. US Pharm 33(6):30-34
Weiss D, Naik P, Weiss R (2009) The 'big pharma' dilemma: develop new drugs or promote exist-
ing ones? Nat Rev Drug Discov 8(7):533-534
Wiggins SN, Maness R (2004) Price competition in pharmaceuticals: the case of anti-infectives.
Econ Inq 42(2):247-263
Search WWH ::
Custom Search